Skip to main content
SpringerLink
Log in

Cholangiocarcinoma

  • Chapter
  • First Online:
Surgical Oncology

Abstract

Cholangiocarcinoma (CCA) is an uncommon but lethal cancer arising from the bile duct epithelium. The clinical presentation depends on the site of origin and stage of the malignancy. The surgical and medical management’s success rate relies highly on early diagnosis. However, there is no specific symptom that will help diagnose the disease at an early stage, which explains CCA’s poor prognosis at the time of diagnosis. Resection with microscopically negative margin (R0 resection) and consideration for a caudate lobectomy, coupled with nodal dissection for extrahepatic cholangiocarcinoma is critical in providing the most favorable outcome. Portal vein embolization followed by extended radical resection, which generally involves major liver resection, and neoadjuvant therapy followed by liver transplantation are options for patients with advanced intrahepatic cholangiocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17; discussion 517–509.

    PubMed  CAS  PubMed Central  Google Scholar 

  2. Morimoto Y, Tanaka Y, Ito T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10(6):432–40.

    PubMed  Google Scholar 

  3. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.

    PubMed  PubMed Central  Google Scholar 

  4. Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol. 2005;11(12):1779–84.

    PubMed  Google Scholar 

  5. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol. 1999;14(12): 1144–9.

    PubMed  CAS  Google Scholar 

  6. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology. 2002;49(44):311–6.

    PubMed  Google Scholar 

  7. Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol. 2003;6(2):105–12.

    PubMed  Google Scholar 

  8. The general rules for the clinical and pathological study of primary liver cancer. The Liver Cancer Study Group. General rules for the clinical and pathological study of primary liver cancer. 2nd Engl. Edn. Tokyo: Kanehara 2003. Jpn J Surg. 1989;19(1):98–129.

    Google Scholar 

  9. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353–7.

    PubMed  CAS  Google Scholar 

  10. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48(6):816–20.

    PubMed  CAS  PubMed Central  Google Scholar 

  11. Monson JR, Donohue JH, Gunderson LL, Nagorney DM, Bender CE, Wieand HS. Intraoperative radiotherapy for unresectable cholangiocarcinoma–the Mayo Clinic experience. Surg Oncol. 1992;1(4):283–90.

    PubMed  CAS  Google Scholar 

  12. Franko J, Nussbaum ML, Morris JB. Choledochal cyst cholangiocarcinoma arising from adenoma: case report and a review of the literature. Curr Surg. 2006;63(4):281–4.

    PubMed  Google Scholar 

  13. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case–control study. Clin Gastroenterol Hepatol. 2007;5(10):1221–8.

    PubMed  PubMed Central  Google Scholar 

  14. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002;2(8):774–9.

    PubMed  Google Scholar 

  15. Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut. 1991;32(11):1369–73.

    PubMed  CAS  PubMed Central  Google Scholar 

  16. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case–control study. Hepatology. 2000;31(1):7–11.

    PubMed  CAS  Google Scholar 

  17. John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig Surg. 2006; 23(5–6):319–24.

    PubMed  CAS  Google Scholar 

  18. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95(1):204–7.

    PubMed  CAS  Google Scholar 

  19. Lindberg B, Arnelo U, Bergquist A, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy. 2002;34(11):909–16.

    PubMed  CAS  Google Scholar 

  20. Johnson SR, Kelly BS, Pennington LJ, Hanto DW. A single center experience with extrahepatic cholangiocarcinomas. Surgery. 2001;130(4):584–90; discussion 590–582.

    PubMed  CAS  Google Scholar 

  21. Lacomis JM, Baron RL, Oliver JH, Nalesnik MA, Federle MP. Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology. 1997;203(1):98–104.

    PubMed  CAS  Google Scholar 

  22. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist. 2006;11(8):913–22.

    PubMed  Google Scholar 

  23. Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology. 2006;238(1):150–5.

    PubMed  Google Scholar 

  24. Fernández-Esparrach G, Ginès A, Sánchez M, et al. Comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of pancreatobiliary diseases: a prospective study. Am J Gastroenterol. 2007;102(8):1632–9.

    PubMed  Google Scholar 

  25. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736–750.e734.

    PubMed  Google Scholar 

  26. Wetter LA, Ring EJ, Pellegrini CA, Way LW. Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). Am J Surg. 1991;161(1):57–62; discussion 62–53.

    PubMed  CAS  Google Scholar 

  27. Witte CL. Choledochal obstruction by cystic duct stone. Mirizzi’s syndrome. Am Surg. 1984;50(5):241–3.

    PubMed  CAS  Google Scholar 

  28. Compton C, Byrd D, Garcia-Aguilar J, et al. Intrahepatic bile ducts. In: Compton C, Byrd D, Garcia-Aguilar J, et al., editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 251–8.

    Google Scholar 

  29. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.

    PubMed  Google Scholar 

  30. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23): 3140–5.

    PubMed  Google Scholar 

  31. Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7.

    PubMed  Google Scholar 

  32. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10(4):288–91.

    PubMed  Google Scholar 

  33. Sano T, Kamiya J, Nagino M, et al. Macroscopic classification and preoperative diagnosis of intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):101–7.

    PubMed  CAS  Google Scholar 

  34. Compton C, Byrd D, Garcia-Aguilar J, et al. Perihilar bile ducts. In: Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M, editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 269–76.

    Google Scholar 

  35. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  36. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2):170–8.

    PubMed  CAS  Google Scholar 

  37. Parikh AA, Abdalla EK, Vauthey JN. Operative considerations in resection of hilar cholangiocarcinoma. HPB (Oxford). 2005;7(4):254–8.

    Google Scholar 

  38. Compton C, Byrd D, Garcia-Aguilar J, et al. Distal bile duct. In: Compton C, Byrd D, Garcia-Aguilar J, et al., editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 277–86.

    Google Scholar 

  39. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89(12):1525–31.

    PubMed  CAS  Google Scholar 

  40. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.

    PubMed  CAS  Google Scholar 

  41. Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005;29(6):728–33.

    PubMed  Google Scholar 

  42. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg. 1999;6(2):122–7.

    PubMed  CAS  Google Scholar 

  43. Couinaud C. Le Foie: Etudes anatomiques et chirurgicales. Paris: Masson; 1957.

    Google Scholar 

  44. Wakai T, Shirai Y, Sakata J, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol. 2007;14(4):1356–65.

    PubMed  Google Scholar 

  45. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1997;185(5): 429–36.

    PubMed  CAS  PubMed Central  Google Scholar 

  46. Chu KM, Lai EC, Al-Hadeedi S, et al. Intrahepatic cholangiocarcinoma. World J Surg. 1997;21(3):301–5; discussion 305–306.

    PubMed  CAS  Google Scholar 

  47. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg. 2000;87(9):1182–7.

    PubMed  CAS  Google Scholar 

  48. Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127(5):498–505.

    PubMed  CAS  Google Scholar 

  49. Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimachi K. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88(11):1463–6.

    PubMed  CAS  Google Scholar 

  50. Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer. 2001;92(9):2374–83.

    PubMed  CAS  Google Scholar 

  51. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2001;50(3):675–80.

    PubMed  CAS  Google Scholar 

  52. Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41(9):893–900.

    PubMed  CAS  Google Scholar 

  53. Smith RR, Gibbs JF. Surgical management of intrahepatic biliary tract cancer. In: Thomas CR, Fuller CD, editors. Biliary tract and gallbladder cancer; 2008. Demos Medical Publishing, New York pp. 181–194

    Google Scholar 

  54. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241–56.

    PubMed  CAS  Google Scholar 

  55. Nishio H, Kamiya J, Nagino M, et al. Value of percutaneous transhepatic portography before hepatectomy for hilar cholangiocarcinoma. Br J Surg. 1999;86(11):1415–21.

    PubMed  CAS  Google Scholar 

  56. Suzuki S, Sakaguchi T, Yokoi Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg. 2002;26(6): 687–93.

    PubMed  Google Scholar 

  57. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15(10):2787–94.

    PubMed  Google Scholar 

  58. Lang H, Sotiropoulos GC, Frühauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005; 241(1):134–43.

    PubMed  PubMed Central  Google Scholar 

  59. Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg. 1998;187(4):365–72.

    PubMed  CAS  Google Scholar 

  60. Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):117–21.

    PubMed  CAS  Google Scholar 

  61. Hemming AW, Reed AI, Langham MR, Fujita S, Howard RJ. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg. 2004;239(5):712–9; discussion 719–721.

    PubMed  PubMed Central  Google Scholar 

  62. Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc. 2013;77(2):167–74.

    PubMed  Google Scholar 

  63. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001;88(2):165–75.

    PubMed  CAS  Google Scholar 

  64. Kokudo N, Makuuchi M. Current role of portal vein embolization/hepatic artery chemoembolization. Surg Clin North Am. 2004;84(2):643–57.

    PubMed  Google Scholar 

  65. Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. 2002;131(1 Suppl):S159–64.

    PubMed  Google Scholar 

  66. Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243(3):364–72.

    PubMed  PubMed Central  Google Scholar 

  67. Uenishi T, Hirohashi K, Kubo S, et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg. 2001;25(7):865–9.

    PubMed  CAS  Google Scholar 

  68. Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8(2):154–7.

    PubMed  CAS  Google Scholar 

  69. Uenishi T, Hirohashi K, Kubo S, et al. Clinicopathologic features in patients with long-term survival following resection for intrahepatic cholangiocarcinoma. Hepato-gastroenterology. 2003;50(52):1069–72.

    PubMed  Google Scholar 

  70. Lee HY, Kim SH, Lee JM, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology. 2006;239(1):113–21.

    PubMed  Google Scholar 

  71. Okumoto T, Sato A, Yamada T, et al. Correct diagnosis of vascular encasement and longitudinal extension of hilar cholangiocarcinoma by four-channel multidetector-row computed tomography. Tohoku J Exp Med. 2009;217(1):1–8.

    PubMed  Google Scholar 

  72. Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2012;11(1):12–7.

    PubMed  CAS  Google Scholar 

  73. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237(5):686–91. discussion 691–683.

    PubMed  PubMed Central  Google Scholar 

  74. Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011;53(4):1363–71.

    PubMed  Google Scholar 

  75. Shindoh J, et al. Isolated sling suspension during resection of the Spiegel lobe of the liver: a safe alternative technique for difficult cases. J Hepatobiliary Pancreat Sci. 2010;17(3):359–64.

    PubMed  Google Scholar 

  76. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg. 2000;7(2):155–62.

    PubMed  CAS  Google Scholar 

  77. Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery. 2007; 141(5):581–8.

    PubMed  Google Scholar 

  78. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14(2):109–14.

    PubMed  CAS  Google Scholar 

  79. Zaydfudim V, Rosen C, Nagorney D. Hilar cholangiocarcinoma. In: Pawlik T, editor. Biliary tract and primary liver tumors, vol. 23(2). Philadelphia: Elsevier; 2014. p. 247–63.

    Google Scholar 

  80. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83(12):1712–5.

    PubMed  CAS  Google Scholar 

  81. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. J Surg Oncol. 1997;64(3):242–5.

    PubMed  CAS  Google Scholar 

  82. Schulick RD. Criteria of unresectability and the decision-making process. HPB (Oxford). 2008;10(2):122–5.

    CAS  Google Scholar 

  83. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg. 2010;251(4):675–81.

    PubMed  Google Scholar 

  84. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997;174(6):605–8; discussion 608–609.

    PubMed  CAS  Google Scholar 

  85. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):148–53.

    PubMed  CAS  PubMed Central  Google Scholar 

  86. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1–9.

    PubMed  PubMed Central  Google Scholar 

  87. Fuks D, Bartoli E, Delcenserie R, et al. Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol. 2009;24(11):1745–52.

    PubMed  CAS  Google Scholar 

  88. Harewood GC, Baron TH, Rumalla A, et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2005;20(3):415–20.

    PubMed  Google Scholar 

  89. Baer HU, Rhyner M, Stain SC, et al. The effect of communication between the right and left liver on the outcome of surgical drainage for jaundice due to malignant obstruction at the hilus of the liver. HPB Surg. 1994;8(1):27–31.

    PubMed  CAS  PubMed Central  Google Scholar 

  90. Suzuki S, Kurachi K, Yokoi Y, et al. Intrahepatic cholangiojejunostomy for unresectable malignant biliary tumors with obstructive jaundice. J Hepatobiliary Pancreat Surg. 2001;8(2):124–9.

    PubMed  CAS  Google Scholar 

  91. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69(8):1633–7.

    PubMed  CAS  Google Scholar 

  92. Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl. 2005; 11(11):1412–6.

    PubMed  Google Scholar 

  93. Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004; 239(2):265–71.

    PubMed  PubMed Central  Google Scholar 

  94. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24(2):201–7.

    PubMed  Google Scholar 

  95. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8; discussion 458–461.

    PubMed  PubMed Central  Google Scholar 

  96. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010;23(7):692–7.

    PubMed  Google Scholar 

  97. Yamamoto M, Ariizumi S. Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma. J Gastroenterol. 2006;41(9):925–6.

    PubMed  Google Scholar 

  98. Benson AB, Bekaii-Saab T, Ben-Josef E, et al. Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006;4(8):728–50.

    CAS  Google Scholar 

  99. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16(2):279–81.

    PubMed  CAS  Google Scholar 

  100. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23(10):2332–8.

    PubMed  CAS  Google Scholar 

  101. Park SH, Park YH, Lee JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006;106(2): 361–5.

    PubMed  CAS  Google Scholar 

  102. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739–47.

    PubMed  Google Scholar 

  103. Cantore M, Mambrini A, Fiorentini G, et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005;103(7): 1402–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, SUNY Buffalo, 100 High St., Buffalo, NY, 14203, USA

    Parham Mafi M.D.

  2. Department of Surgery, LSU Health Sciences Center-Shreveport, 1501 Kings Hwy, 33932, Shreveport, LA, 71130-3932, USA

    Quyen D. Chu M.D., MBA, FACS

  3. Department of Surgery, Tripler Army Medical Center, 1 Jarrett White Rd., Honolulu, HI, 96859, USA

    Richard R. Smith M.D.

  4. Department of Surgery, Jersey Shore University Medical Center/Meridian Heath, 1945 State Highway 33, 4 floor Ackerman, Neptune, NJ, 07753, USA

    John F. Gibbs M.D.

Authors
  1. Parham Mafi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quyen D. Chu M.D., MBA, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard R. Smith M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John F. Gibbs M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. Gibbs M.D. .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mafi, P., Chu, Q.D., Smith, R.R., Gibbs, J.F. (2015). Cholangiocarcinoma. In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation